Previous 10 | Next 10 |
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Bank of America Securities 2020 Napa Biopharma Conference on Wednesday, June 24, 2020 at 10:30 am PT (1:30 pm ET) via webcast. A li...
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more ...
− The ENVISION Phase 3 Study Evaluated the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyria (AHP) − − Givosiran Demonstrated Significant Reduction in the Rate of Porphyria Attacks Compared with Placebo in Patients with AHP – Al...
Market Pulse The question of whether it's a new bull market rally or just an intermittent bear market rally doomed to end later this year will most likely be decided late in the third quarter or during the fourth quarter when enough evidence on the durability of the recovery pace is forthcom...
Sorrento Provides Positive Update for COVIDTRAP Sorrento Therapeutics Inc. ( SRNE ) announced completing the preclinical batch of COVIDTRAP protein. The company reported that it has obtained positive results from preclinical testing of the drug candidate STI-4398. Sorrento plans to devel...
Alnylam ( ALNY ) is well on its way to having its third commercial product before the end of 2020. A prior release of positive top-line data from the company's pivotal ILLUMINATE-A study of lumasiran already indicated approvable efficacy, but the full data presented on Sunday June 7 added ...
What bear market? And just like that, Regeneron's ( REGN ) bear market is gone. Years of striking out with a drug the company believed in (Praluent) or hitting a bunt single with another one it overestimated (Kevzara) have been erased with the latest surge in the stock that recently eclipsed...
Following up on its initial announcement in December 2019, Alnylam Pharmaceuticals (NASDAQ: ALNY ) releases detailed result s from its successful Phase 3 clinical trial, ILLUMINATE-A , evaluating RNAi therapeutic candidate lumasiran in patients with primary hyperoxaluria type 1 (PH1), a ...
- Lumasiran Achieved Primary Endpoint with 53.5 Percent Mean Reduction in Urinary Oxalate Relative to Placebo and Showed a 65.4 Percent Reduction Relative to Baseline - - 84 Percent of Patients on Lumasiran Achieved Normal or Near-Normal Levels of Urinary Oxalate and More than Half of ...
− Program Recognizes Seven Patient Advocacy Groups Addressing Unmet Needs Among Three Rare Disease Communities − Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that seven patient advocacy groups will receive supporti...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...